Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
701 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2025 Experimental Therapy Poland 57,2
702 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 3,1
703 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 3,4
704 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 2,8
705 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 5,9
706 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 11,9
707 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2025 Experimental Therapy Poland 54,2
708 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2025 Experimental Therapy Poland 78,4
709 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 6,8
710 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2025 Experimental Therapy Poland 58,2
711 Cord Tissue Autologous Autism Neurology 2025 Experimental Therapy Romania 5
712 Cord Tissue Allogeneic – Related Autism Neurology 2025 Experimental Therapy Romania 5
713 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 4,1
714 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 7,9
715 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 7,8
716 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2025 Experimental Therapy Poland 25,8
717 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 6,8
718 Cord Tissue Allogeneic – Unrelated Progressive bulbar palsy Neurology 2025 Experimental Therapy Poland 62,3
719 Cord Tissue Allogeneic – Unrelated Encephalopathy Neurology 2025 Experimental Therapy Poland 67,2
720 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 7,8
721 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2025 Experimental Therapy Poland 61,9
722 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 5,11
723 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 6,8
724 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 1,5
725 Cord Tissue Allogeneic – Unrelated Myelitis Neurology 2025 Experimental Therapy Poland 38,8
726 Cord Tissue Allogeneic – Unrelated Anemia Neurology 2025 Experimental Therapy Poland 3,2
727 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 6,8
728 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 7,1
729 Cord Tissue Allogeneic – Unrelated Spinocerebellar Ataxia Neurology 2025 Experimental Therapy Poland 5,1
730 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 1,2
731 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 1,1
732 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 5,11
733 Cord Tissue Allogeneic – Unrelated Progressive bulbar palsy Neurology 2025 Experimental Therapy Poland 63
734 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 15,2
735 Cord Tissue Allogeneic – Unrelated GvHD Immunology 2025 Experimental Therapy Poland 13
736 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2025 Experimental Therapy Poland 48,2
737 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2025 Experimental Therapy Poland 51,6
738 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2025 Experimental Therapy Poland 12,9
739 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 10,1
740 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 8,4
741 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 3,7
742 Cord Tissue Allogeneic – Unrelated Cerebral Infarction Neurology 2025 Experimental Therapy Poland 57,8
743 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 7,7
744 Cord Tissue Allogeneic – Unrelated Cerebellar Syndrome Neurology 2025 Experimental Therapy Poland 43,4
745 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2025 Experimental Therapy Poland 61,1
746 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2025 Experimental Therapy Poland 57,9
747 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 1,2
748 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2025 Experimental Therapy Poland 7,1
749 Cord Tissue Allogeneic – Unrelated Autism Neurology 2025 Experimental Therapy Poland 3
750 Cord Blood Allogeneic – Related Thalassemia Major Hematology 2025 Standard Therapy Turkey 5,9
751 Cord Blood Autologous Aplastic Anemia Hematology 2025 Standard Therapy Poland 2
752 Cord Blood Allogeneic – Related Thalassemia Major Hematology 2025 Standard Therapy Turkey 6,8
753 Cord Blood Allogeneic – Related Cerebral Palsy Neurology 2025 Experimental Therapy Portugal 1 year and 8 months
754 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Romania 5
755 Cord Blood Allogeneic Acute lymphoblastic leukemia Hematology 2025 Standard Therapy Poland 13
756 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 5 ,5
757 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 7,2
758 Cord Blood Allogeneic Thalassemia Major Hematology 2025 Standard Therapy Turkey 10,9
759 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 4,1
760 Cord Blood Autologous Cerebral Palsy Neurology 2025 Experimental Therapy Poland 3,1
761 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 5,2
762 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 2,11
763 Cord Blood Autologous Unbalanced AVSD Cardiovascular 2025 Experimental Therapy Poland 5 months
764 Cord Blood Allogeneic – Related Relapsed Lymphoblastic Leukemia Hematology 2025 Standard Therapy Turkey 8,5
765 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 10,1
766 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 5,7
767 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 4,4
768 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 5,5
769 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 5,4
770 Cord Blood Autologous Autism Neurology 2025 Experimental Therapy Poland 3,9
771 Cord Blood Allogeneic – Related D57.1 Sickle Cell Anemia Hematology 2025 Standard Therapy Turkey 5 years 6 months
772 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 66
773 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
774 Bone Marrow Family Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Poland 71
775 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 72
776 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 47
777 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Ukraine 43
778 Bone Marrow Family Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 49
779 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 51
780 Bone Marrow Family Allogeneic Philadelphia – positive Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 61
781 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 58
782 Bone Marrow Family Allogeneic Myelofibrosis Hematology 2025 Standard Therapy NETHERLANDS 63
783 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
784 Bone Marrow Family Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy France 63
785 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 68
786 Bone Marrow Family Allogeneic Myelofibrosis Hematology 2025 Standard Therapy France 71
787 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russia 51
788 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
789 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Czechia 54
790 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 16
791 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 61
792 Bone Marrow Family Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Poland 61
793 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 70
794 Bone Marrow Family Allogeneic PostET Myelofibrosis Hematology 2025 Standard Therapy Netherlands 21
795 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 68
796 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia/ Mielodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
797 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy NETHERLANDS 60
798 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 33
799 Bone Marrow Family Allogeneic Muscular Dystrophy Association Hematology 2025 Standard Therapy United Kingdom 75
800 Bone Marrow Family Allogeneic Acute Myeloid Leukemia Hematology 2025 Standard Therapy Germany 72
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?